Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030”, covering various important aspects of the industry and identifying key future growth opportunities.
To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Key Market Insights
- More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis
- The market is fragmented, featuring both established players and new entrants, which claim to operate at various scales and manufacture a diverse range of cell therapies
- In order to cater to the growing needs of clients / sponsors, companies have established presence across different regions; presently, the US, the UK and China are the key hubs for cell therapy manufacturing
- In recent years, a significant increase in partnership activity has been observed in this domain; in fact, therapy developers have already inked manufacturing deals with both indigenous and international experts
- In order to enhance core competencies related to the domain, both drug developers and CMOs are actively investing in expanding their existing infrastructure and capabilities
- Cell therapy manufacturers are also gradually opting to automate various operations in the supply chain; the primary objective is to achieve favorable bench-to-clinic timelines and cut down on production related losses
- Currently, the installed global capacity for cell therapy manufacturing is estimated to be spread across 1.2+ million square feet of dedicated cleanroom area distributed across various scales of operation
- More than 70,000 patients were estimated to have been enrolled in cell therapy related clinical trials; the demand for cell therapies is anticipated to grow significantly over the next decade
Revenues from manufacturing operations of T-cell therapies are anticipated to capture higher market share; the benefit will be realized by both autologous and allogeneic therapies across different regions the world
Clinical scale manufacturing operations are likely to drive the future market size, taking into consideration both in-house and contract service requirements
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
